ARTICLE | Company News

Genzyme begins shipping Fabrazyme

March 2, 2012 1:54 AM UTC

Genzyme Corp. said it began shipping Fabry's disease therapy Fabrazyme agalsidase beta manufactured at its newly approved Framingham, Mass., facility. The company said U.S. patients will able to return to full dosing this month and all new U.S. patients are eligible to begin treatment at full dosing levels. Additionally, the most severely affected patients in Europe will begin receiving full doses of Fabrazyme this month. Genzyme said the return to normal global supply levels of Fabrazyme will begin next quarter. FDA and EMA approved the facility in January. ...